News Release

Printer Friendly Version View printer-friendly version << Back
October 16, 2019 at 4:05 PM EDT

SeaSpine to Report Third Quarter 2019 Financial Results on October 29, 2019

Corresponding Conference Call and Webcast with Accompanying Slides to Discuss Results Available on SeaSpine Website at 4:30pm ET

CARLSBAD, Calif., Oct. 16, 2019 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release third quarter 2019 financial results after the close of trading on Tuesday, October 29, 2019. Members of the Company’s management will host a corresponding conference call and webcast with accompanying slides beginning at 1:30pm PT / 4:30pm ET to discuss the financial results and the Company’s business.

Individuals interested in listening to the conference call may do so by dialing (877) 418-4766 for domestic callers or (614) 385-1253 for international callers, using Conference ID: 1369654. To listen to a live webcast and to access the corporate presentation, please visit the Investors section of the SeaSpine website at: www.seaspine.com.

About SeaSpine
SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Expertise in both orthobiologic sciences and spinal implants product development allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide through a committed network of increasingly exclusive distribution partners.

Investor Relations Contact   
Leigh Salvo
(415) 937-5402
ir@seaspine.com

SeaSpine logo

Source: SeaSpine Holdings Corporation